Timosaponin AIII suppresses hepatocyte growth factor-induced invasive activity through sustained ERK activation in breast cancer MDA-MB-231 cells

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Tsai, Chung Hsin ^a,b   Yang, Chu Wen ^c   Wang, Jir You ^d   Tsai, Yi Fang ^d   Tseng, Ling Ming ^a,d   King, Kuan Liang ^d   Chen, Wei Shone ^d   Chiu, Jen Hwey ^a,d,e   Shyr, Yi Ming ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c SOOCHOW UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; SAPONIN DERIVATIVE; SCATTER FACTOR; STEM CELL FACTOR; TIMOSAPONIN III; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

EID: 84880144778     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/421051     Document Type: Article

References (33)

1. Bureau of Health Promotion, Department of Health, R.O.C., 2009
2. Foulkes W. D., Smith I. E., Reis-Filho J. S., Triple-negative breast cancer. The New England Journal of Medicine 2010 363 20 1938 1948 2-s2.0-78149483057 10.1056/NEJMra1001389
3. Thike A. A., Cheok P. Y., Jara-Lazaro A. R., Tan B., Tan P., Tan P. H., Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Modern Pathology 2010 23 1 123 133 2-s2.0-73949139019 10.1038/modpathol.2009.145
4. Furukawa T., Duguid W. P., Kobari M., Matsuno S., Tsao M.-S., Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. The American Journal of Pathology 1995 147 4 889 895 2-s2.0-0028801180
5. Aoki T., Tsukinoki K., Kurabayashi H., Sasaki M., Yasuda M., Ota Y., Watanabe Y., Kaneko A., Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors. Oral Oncology 2006 42 1 51 56 2-s2.0-29244433574 10.1016/j.oraloncology.2005.06.012 (Pubitemid 41831522)
6. Siegfried J. M., Gubish C. T., Rothstein M. E., de Oliveira P. E. Q., Stabile L. P., Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non-small-cell lung cancer. Molecular Pharmacology 2007 72 3 769 779 2-s2.0-34548304315 10.1124/mol.107.034215 (Pubitemid 47347312)
7. Burstein H. J., Elias A. D., Rugo H. S., Cobleigh M. A., Wolff A. C., Eisenberg P. D., Lehman M., Adams B. J., Bello C. L., DePrimo S. E., Baum C. M., Miller K. D., Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology 2008 26 11 1810 1816 2-s2.0-42949148257 10.1200/JCO.2007.14.5375
8. Molassiotis A., Fernandez-Ortega P., Pud D., Ozden G., Scott J. A., Panteli V., Margulies A., Browall M., Magri M., Selvekerova S., Madsen E., Milovics L., Bruyns I., Gudmundsdottir G., Hummerston S., Ahmad A. M.-A., Platin N., Kearney N., Patiraki E., Use of complementary and alternative medicine in cancer patients: a European survey. Annals of Oncology 2005 16 4 655 663 2-s2.0-20944445252 10.1093/annonc/mdi110 (Pubitemid 40613334)
9. Burstein H. J., Gelber S., Guadagnoli E., Weeks J. C., Use of alternative medicine by women with early-stage breast cancer. The New England Journal of Medicine 1999 340 22 1733 1739 2-s2.0-0033519663 10.1056/NEJM199906033402206 (Pubitemid 29252602)
10. Shoemaker M., Hamilton B., Dairkee S. H., Cohen I., Campbell M. J., In vitro anticancer activity of twelve Chinese medicinal herbs. Phytotherapy Research 2005 19 7 649 651 2-s2.0-25444513400 10.1002/ptr.1702 (Pubitemid 41375251)
11. Takeda Y., Togashi H., Matsuo T., Shinzawa H., Takeda Y., Takahashi T., Growth inhibition and apoptosis of gastric cancer cell lines by Anemarrhena asphodeloides Bunge. Journal of Gastroenterology 2001 36 2 79 90 2-s2.0-0035084140 10.1007/s005350170135 (Pubitemid 32237076)
12. Sy L.-K., Yan S.-C., Lok C.-N., Man R. Y. K., Che C.-M., Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in hela cancer cells. Cancer Research 2008 68 24 10229 10237 2-s2.0-57749085555 10.1158/0008-5472.CAN-08-1983
13. Lin C.-W., Shen S.-C., Hou W.-C., Yang L.-Y., Chen Y.-C., Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Molecular Cancer Therapeutics 2008 7 5 1195 1206 2-s2.0-49849103925 10.1158/1535-7163.MCT-07-2199
14. Bradford M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry 1976 72 1-2 248 254 2-s2.0-0017184389
15. Yang C.-W., Chang C.-L., Lee H.-C., Chi C.-W., Pan J.-P., Yang W.-C., Curcumin induces the apoptosis of human monocytic leukemia THP-1 cells via the activation of JNK/ERK Pathways. BMC Complementary and Alternative Medicine 2012 12, article 22 2-s2.0-84858712937 10.1186/1472-6882-12-22
16. Chomczynski P., Sacchi N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987 162 1 156 159 2-s2.0-0023277545 (Pubitemid 17064313)
17. Jones M. K., Sasaki E., Halter F., Pai R., Nakamura T., Arakawa T., Kuroki T., Tarnawski A. S., HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB Journal 1999 13 15 2186 2194 2-s2.0-0032787558
18. Chen J.-H., Wu C.-W., Kao H.-L., Chang H.-M., Li A. F.-Y., Liu T.-Y., Chi C.-W., Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Letters 2006 239 2 263 270 2-s2.0-33745660109 10.1016/j.canlet.2005.08.026 (Pubitemid 43974872)
19. Krysan K., Reckamp K. L., Sharma S., Dubinett S. M., The potential and rationale for COX-2 inhibitors in lung cancer. Anti-Cancer Agents in Medicinal Chemistry 2006 6 3 209 220 2-s2.0-33744471666 10.2174/187152006776930882 (Pubitemid 43796639)
20. Martey C. A., Pollock S. J., Turner C. K., O'Reilly K. M. A., Baglole C. J., Phipps R. P., Sime P. J., Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. The American Journal of Physiology 2004 287 5 L981 L991 2-s2.0-6344263598 10.1152/ajplung.00239.2003 (Pubitemid 39391028)
21. Yoshimoto A., Kasahara K., Kawashima A., Fujimura M., Nakao S., Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncology Reports 2005 13 6 1049 1057 2-s2.0-24744438296
22. Cagnol S., Chambard J.-C., ERK and cell death: mechanisms of ERK-induced cell death: apoptosis, autophagy and senescence. FEBS Journal 2010 277 1 2 21 2-s2.0-73649089980 10.1111/j.1742-4658.2009.07366.x
23. Martin P., Pognonec P., ERK and cell death: cadmium toxicity, sustained ERK activation and cell death. FEBS Journal 2010 277 1 39 46 2-s2.0-73649143489 10.1111/j.1742-4658.2009.07369.x
24. King F. W., Fong S., Griffin C., Shoemaker M., Staub R., Zhang Y.-L., Cohen I., Shtivelman E., Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. PLoS ONE 2009 4 9 2-s2.0-70349645385 10.1371/journal.pone.0007283 e7283
25. Tazawa R., Xu X.-M., Wu K. K., Wang L.-H., Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochemical and Biophysical Research Communications 1994 203 1 190 199 2-s2.0-0028047951 10.1006/bbrc.1994.2167 (Pubitemid 24281079)
26. Recio J. A., Merlino G., Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002 21 7 1000 1008 2-s2.0-0037034199 10.1038/sj/onc/1205150 (Pubitemid 34174512)
27. Knippen S., Löning T., Müller V., Schröder C., Jänicke F., Milde-Langosch K., Expression and prognostic value of activating transcription factor 2 (atf2) and its phosphorylated form in mammary carcinomas. Anticancer Research 2009 29 1 183 190 2-s2.0-61449155619
28. Bhoumik A., Ronai Z., ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 2008 7 15 2341 2345 2-s2.0-48849111311
29. Berger A. J., Kluger H. M., Li N., Kielhorn E., Halaban R., Ronai Z., Rimm D. L., Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003 63 23 8103 8107 2-s2.0-0346365379 (Pubitemid 37549453)
30. Hwang E.-S., Park K.-K., Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Bioscience, Biotechnology and Biochemistry 2010 74 5 961 967 2-s2.0-77955375922 10.1271/bbb.90785
31. Hanemaaijer R., Verheijen J. H., Maguire T. M., Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. International Journal of Cancer 2000 86 204 207 (Pubitemid 30180815)
32. Pellikainen J. M., Ropponen K. M., Kataja V. V., Kellokoski J. K., Eskelinen M. J., Kosma V.-M., Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clinical Cancer Research 2004 10 22 7621 7628 2-s2.0-9344271530 10.1158/1078-0432.CCR-04-1061 (Pubitemid 39557525)
33. Gratus C., Wilson S., Greenfield S. M., Damery S. L., Warmington S. A., Grieve R., Steven N. M., Routledge P., The use of herbal medicines by people with cancer: a qualitative study. BMC Complementary and Alternative Medicine 2009 9, article 14 2-s2.0-66749192042 10.1186/1472-6882-9-14